Nelis G F
Department of Internal Medicine, Sophia Ziekenhuis, Zwolle, The Netherlands.
Digestion. 1989;44 Suppl 1:68-76. doi: 10.1159/000200106.
Omeprazole is a very potent inhibitor of gastric acid secretion and has proven to be efficacious in the healing of peptic ulcer and reflux oesophagitis. A search for adverse events during short-term treatment with omeprazole has been made, based on data from published comparative trials, data on file at the manufactor's (Hässle Research Laboratories, Mölndal, Sweden) and personal series. Omeprazole does not show more adverse events than drugs currently widely in use for the treatment of acid-related disorders. A change in a wide range of laboratory parameters has not been observed, except for a rise in basal and meal-stimulated serum gastrin which can be ascribed directly to the inhibition of acid secretion. For short-term treatment omeprazole can be considered as a safe drug.
奥美拉唑是一种非常强效的胃酸分泌抑制剂，已被证明对消化性溃疡和反流性食管炎的愈合有效。基于已发表的对比试验数据、制造商（瑞典莫伦德尔哈塞尔研究实验室）存档数据以及个人病例系列，对奥美拉唑短期治疗期间的不良事件进行了调查。与目前广泛用于治疗酸相关疾病的药物相比，奥美拉唑并未显示出更多的不良事件。除了基础和餐后刺激血清胃泌素升高可直接归因于胃酸分泌抑制外，未观察到广泛的实验室参数变化。对于短期治疗，奥美拉唑可被视为一种安全的药物。
